Dr. Nagle is a Professor Emeritus of Pathology, Cell Biology and Anatomy, and Surgery at The University of Arizona, and former medical director at Ventana Medical Systems in Tucson, Arizona. He previously served as Deputy Director (1997-2003) and Interim Director (2003-2005) of The University of Arizona Cancer Center.
His major research interests involve molecular pathology studies in prostate carcinogenesis. His research program has focused for the past several years on understanding the biological basis for the variability in the clinical evolution and spread of prostate cancer. In collaboration with Drs. Anne Cress, Timothy Bowden, Ronald Heimark and many others, his group has worked to define molecular events during the progression of the disease that allow the cancer to migrate out of the site of origin in the prostate and thus metastasize to the bone and other sites. Such knowledge may provide the basis for predicting the probable outcome of an individual’s tumor as well as suggest approaches to block the evolution and dissemination of prostate cancer.
Dr. Nagle received combined training in anatomic and clinical pathology at the University of Washington. Subsequently, he received an NIH post-doctoral fellowship in experimental pathology which led to a Ph.D. degree. He was an associate pathologist in the Department of Experimental Pathology at Walter Reed Army Institute of Research where he was involved in studies of pathogenesis of African Trypanosomiasis as well as acute renal failure. Following military service, he served on the faculty at the University of Maryland where his research primarily dealt with mechanisms of acute renal failure as well as models of experimental glomerulonephritis. In 1968 he joined the faculty at the University of Arizona College of Medicine. His work as a surgical pathologist led to a research program focusing on the role and identification of cytokeratins in the diagnosis of human neoplasms.
Dr. Nagle has over 28 funded research grants, and has authored over 180 papers and abstracts in the area of solid tumor pathology and prostate cancer progression.